Monoclonal Antibodies in Acute Lymphocytic Leukemia

Therapies targeting either specific transcripts (e.g. BCR-ABL1 tyrosine kinase oncoprotein by tyrosine kinase inhibitors) or specific leukemic cell surface antigens (e.g. CD20, CD22, and CD19 monoclonal antibodies) are major breakthroughs in the treatment of acute lymphocytic leukemia (ALL). Monoclonal antibodies hold significant promise in improving the outcomes of patients with ALL. Rituximab has been shown to improve overall survival in patients with CD20-positive ALL, and next-generation anti-CD20 antibodies may be able to further improve these outcomes.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research